News


All series


All News

In an interview with&nbsp;<em>Targeted Oncology</em>, Paul G. Richardson, MD,&nbsp;clinical program leader and director of Clinical Research in the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute,&nbsp;discussed the results from the OPTIMISMM trial. He also shared his insight on the significance of these findings and what he expects to see in the future for this patient population.

Filgrastim-aafi, a filgrastim biosimilar, has been approved by the FDA to treat side effects associated with&nbsp;cancer treatment, including febrile neutropenia and severe neutropenia, according to an announcement from Pfizer, the manufacturer of the biosimilar.

Ivosidenib (Tibsovo) has been granted approval by the FDA for the treatment of&nbsp;adult patients with relapsed/refractory <em>IDH1</em>-mutant acute myeloid leukemia.

Maintenance rituximab improved progression-free survival and overall survival following induction chemoimmunotherapy for&nbsp;patients with mantle cell lymphoma, according to results of a recent meta-analysis.<br /> &nbsp;

A biologics license application for sacituzumab govitecan has been granted a priority review by the FDA&nbsp;for the treatment of patients with metastatic triple-negative breast cancer following at least 2 prior therapies for metastatic disease, Immunomedics, the manufacturer of the antibody-drug conjugate, has announced.

Upfront&nbsp;ribociclib (Kisqali) has been granted approval by the FDA&nbsp;for use in combination with an aromatase inhibitor (AI) for the treatment of pre/perimenopausal or postmenopausal women with HR-positive/HER2-negative advanced or metastatic breast cancer.&nbsp;Additionally, ribociclib was approved in combination with fulvestrant for postmenopausal women with HR-positive/HER2-negative advanced or metastatic breast cancer.

Patients aged &ge;62 years with melanoma were more likely to respond to treatment with pembrolizumab than younger patients, according to results published in <em>Clinical Cancer Research. </em>Investigators at The Wistar Institute in Philadelphia concluded that the risk for progression following anti&ndash;PD-1 therapy declined by 13% with each decade of life.

Now that chimeric antigen receptor T-cell therapies have received FDA approval for diffuse large B-cell lymphoma (DLBCL) after moving quickly through early phase clinical trials, research is now exploring ways to&nbsp;shift these agents earlier in the treatment paradigm, according to a discussion at the 2nd Annual Live Medical Crossfire on Hematologic Malignancies.

While the approval of new agents represents a great step forward in the treatment of&nbsp;chronic lymphocytic leukemia (CLL), physicians are now challenged with how to best utilize these new treatment options,&nbsp;according to a presentation by Anthony Mato, MD, MSCE, at the 2nd Annual Live Medical Crossfire: Hematologic Malignancies.

The FDA has received a supplemental New Drug Application for venetoclax in combination with&nbsp;a hypomethylating agent or low-dose cytarabine as a frontline treatment for&nbsp;patients with acute myeloid leukemia who are ineligible for intensive chemotherapy, Genentech, the manufacturer of the BCL-2 inhibitor, has announced.

An updated analysis of obinutuzumab alone or in combination with chemotherapy for patients with treatment-na&iuml;ve or relapsed/refractory chronic lymphocytic leukemia detected no new safety signals. Investigators in the phase IIIb GREEN trial also found overall response rates greater than 80% at 3 months post-treatment in some patients.